science

Voclosporin

Voclosporin is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Voclosporin rather than just read about it. In short: Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis. It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability.

Key takeaways

Voclosporin belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Voclosporin to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Voclosporin from memory before moving on to harder problems.

Reference excerpt

Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis. It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability. It was approved for medical use in the United States in January 2021, and in the European Union in September 2022. The U.S. Food and Drug Administration considers it to be a first-in-class medication.

Chemistry Chemically, cyclosporine, a frequently prescribed calcineurin inhibitor, is the source of voclosporin. However, structural changes have been made to voclosporin in order to increase its effectiveness, metabolic stability, and safety. Voclosporin and cyclophilin A combine to produce a heterodimeric complex that binds to and inhibits calcineurin, a calcium-dependent phosphatase implicated in cytokine generation and T-cell activation. According to X-ray crystallography, the sidechain modification at amino acid 1 in voclosporin changes how the cyclophilin-voclosporin complex binds to a surface composed of catalytic and regulatory subunits in calcineurin (the "latch region"); this change in binding results in potent inhibition of calcineurin.The major site for voclosporin metabolism is also moved to amino acid 9, where the resultant IM9 metabolite, which is nearly eight times less powerful than voclosporin, accounts for 16.7% of all drug-related exposure. Contrarily, cyclosporine undergoes extensive metabolism to produce a number of metabolites, including AM1 and AM19, the production of which is greater than that of IM9; in transplant patients, AM1 concentrations and total exposure levels are higher than or comparable to those of cyclosporine, and both AM1 and AM19 have been linked to nephropathy (nephrotoxicity). There should be little competitive inhibition of the parent drug by its less active metabolite due to the low metabolite load associated with voclosporin.

Medical uses Lupus nephritis is a common form of glomerular nephritis occurring in patients with systemic lupus nephritis. Lupus nephritis commonly leads patients to chronic kidney failure and therefore places an emphasis on early intervention for improving treatment outcomes. It is a significant risk factor for morbidity and mortality in systemic lupus erythematosus. The management of lupus nephritis comprises immunosuppressive therapy to lessen inflammation and maintain renal function. Guidelines for managing lupus nephritis are provided by the Kidney Disease Improving Global Outcomes (KDIGO) and the European League Against Rheumatism/European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA). Both sets of recommendations place a strong emphasis on the necessity of lowering proteinuria, a crucial indicator of long-term renal success, and achieving complete renal response (CRR) as treatment objectives. Early intervention with voclosporin in combination with kidney response is believed to lead to more positive clinical outcomes for lupus nephritis patients. Thus, voclosporin is used in combination with background immunosuppressive regimen for the treatment of lupus nephritis. Safety has not been established in combination with cyclophosphamide. Since decreasing proteinuria in the first year of treatment of lupus nephritis is known to be associated with improved long-term outcomes, the available clinical data support the use of voclosporin as first-line therapy in combination with mycophenolate mofetil and low-dose glucocorticosteroid.

Contraindications Patients who are breastfeeding or plan to breastfeed should not take this medication as it may cause fetal harm. Voclosporin is not recommended in patients with a baseline eGFR less than or equal to 45 ml/min/1.73 m2 unless benefits exceeds risk. Dose should be reduced if the drug is used within this population as well as for patients who are hepatically impaired. Avoid the use of live attenuated vaccines when patients are on this medication. Avoid co-administration of voclosporin and other moderate to strong CYP3A4 inhibitors and if needed then reduce the dose of voclosporin. Dosages of PgP-substrate drugs should be reduced if co-administered with voclosporin.

Adverse effects Voclosporin has a boxed warning for malignancies and serious infections. Patients taking Voclosporin along with other immunosuppressants have an increased risk for developing malignancies and serious infections that may lead to hospitalization or death. The most common adverse reactions of voclosporin were (>3%), glomerular filtration rate decreased, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain(upper), dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue. tremor, acute kidney injury, and decreased appetite. Glomerular filtration rate decrease was the most frequently reported adverse reaction, reported in placebo (11.3 per 100 patient-years), LUPKYNIS 23.7 mg (37.1 per 100 patient-years), and voclosporin 39.5 mg BID (48.7 per 100 patient-years). With LUPKYNIS 23.7 mg BID, decreases in glomerular filtration rate occurred within the first 3 months in 71% of patients, with 78% of those resolved or improved following dose modification, and of those 64% resolved or improved within 1 month. Decreases in glomerular filtration rate resulted in permanent discontinuation of LUPKYNIS in 14% of patients and resolved in 40% within 3 months after treatment discontinuation.

… excerpt ends here. Continue reading the full article.

Illustrations

Worked examples

Example 1 — a first encounter with Voclosporin

Start with the simplest possible case. Write down what Voclosporin claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Voclosporin before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Voclosporin ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Voclosporin

In research: Voclosporin appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Voclosporin in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Voclosporin is common in secondary-school and first-year university syllabi. It links to neighbouring topics Cyclic peptides, Immunosuppressants, Peptides, so understanding it makes those chapters shorter.
In everyday life: Look for Voclosporin outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Voclosporin” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Voclosporin in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Voclosporin means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Voclosporin out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Voclosporin in simple terms?

Why does Voclosporin matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Voclosporin?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Voclosporin.